BMS buys back early oncology rights from Asia partner


Bristol-Myers Squibb ($BMY) was aiming for a “creative” development approach to help it develop and commercialize a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint to treat solid tumors. It outlicensed the candidate, BMS-777607, to Asia-focused Aslan Pharmaceutical in 2011 to that aim.

But now--almost 5 years later--the pair hasn’t made much progress. BMS-777607 (ASLAN002) has completed a Phase I trial in which it was shown to be safe--and it demonstrated inhibition of RON that was reflected in plasma activity biomarkers.

Still, Bristol-Myers is buying back BMS-777607. It will pay an upfront of $10 million, along with potential development and regulatory milestones of more than $50 million. Aslan will also stand to receive royalties on worldwide sales.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

Aslan was founded in 2010 and has since raised about $100 million with the intention of in-licensing preclinical and early clinical candidates from pharmas in oncology, respiratory and inflammation disease indications.

The original deal had given Aslan exclusive rights to develop and commercialize BMS-777607 in China, Australia, Korea, Taiwan and some other Asian countries. The goal had been to get through clinical proof-of-concept under a program run and funded by Aslan that would start by targeting gastric cancer and lung cancer.

Singapore-based Aslan, which raised $23 million from Asian investors in June ahead of an anticipated IPO, is working to position this as a win.

“The acquisition of ASLAN002 by Bristol-Myers Squibb supports Aslan’s strategy to in-license investigational programmes and apply the unique development expertise of our team to accelerate the generation of high-quality data and significantly increase the value of a programme,” said Aslan CEO Dr. Carl Firth in a statement. “The commercial terms of the agreement further strengthen Aslan’s financial position following the closing of our recent financing rounds; we are in a very strong position to continue to build our proprietary pipeline of novel clinical programmes.”

Aslan’s two most advanced candidates are in Phase II testing: varlitinib, a pan-HER inhibitor in development in cholangiocarcinoma, gastric and breast cancers that’s in-licensed from Array Biopharma ($ARRY), and ASLAN002, a RON and MET inhibitor being developed for gastric and breast cancers.

- here is the release

Related Articles:
Aslan raises $23M in pre-IPO round from new, existing investors
Aslan gets U.S. FDA orphan designation on ASLAN001
Aslan and Singapore's NCCS plan studies on Asia-prevalent cancers

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.